| Id: | acc4192 |
| Group: | 1sens |
| Protein: | ERK1 |
| Gene Symbol: | Mapk3 |
| Protein Id: | Q63844 |
| Protein Name: | MK03_MOUSE |
| PTM: | phosphorylation |
| Site: | Tyr204 |
| Site Sequence: | EHDHTGFLTEYVATRWYRAPE |
| Disease Category: | Nervous system diseases |
| Disease: | Cognitive Abnormalities |
| Disease Subtype: | Cognitive Impairment |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | Lotus seedpod procyanidins |
| Drug Info: | Lotus seedpod procyanidins are a type of plant-derived compound that may have various health benefits. |
| Effect: | modulate |
| Effect Info: | "Moreover, lotus seedpod procyanidins (LSPCs) can reverse the excessive phosphorylation of JNK caused by extremely low-frequency electromagnetic field exposure and restore the phosphorylation levels of ERK/CREB." |
| Note: | |
| Score: | 4.0 |
| Pubmed(PMID): | 25066354 |
| Sentence Index: | 25066354_0 |
| Sentence: | "Extremely low frequency electromagnetic field exposure causes cognitive impairment associated with alteration of the glutamate level, MAPK pathway activation and decreased CREB phosphorylation in mice hippocampus: reversal by procyanidins extracted from the lotus seedpod." |
Sequence & Structure:
MAAAAAAPGGGGGEPRGTAGVVPVVPGEVEVVKGQPFDVGPRYTQLQYIGEGAYGMVSSAYDHVRKTRVAIKKISPFEHQTYCQRTLREIQILLRFRHENVIGIRDILRAPTLEAMRDVYIVQDLMETDLYKLLKSQQLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLINTTCDLKICDFGLARIADPEHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINMKARNYLQSLPSKTKVAWAKLFPKSDSKALDLLDRMLTFNPNKRITVEEALAHPYLEQYYDPTDEPVAEEPFTFDMELDDLPKERLKELIFQETARFQPGAPEGP
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| T | 203 | U | Squamous cell carcinoma | Phosphorylation | 19934324 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
